King Charles House
Park End Street
About Evox Therapeutics
Evox Therapeutics is a privately held, Oxford-based biotechnology company focused on harnessing and engineering the natural delivery capabilities of extracellular vesicles, known as exosomes, to develop an entirely new class of biotherapeutics.
Founders: Matthew Wood, Per Lundin and Samir EL Andaloussi
CEO: Antonin de Fougerolles
COO: Per Lundin
25 articles with Evox Therapeutics
Landmark paper highlights Evox Therapeutics' cutting edge exosome engineering approach for enhanced surface display of biologics
Evox Therapeutics Ltd, a leading exosome therapeutics company, announces that it has, in close collaboration with one of its co-founder's lab at the Karolinska Institute, published a landmark paper in Nature Biomedical Engineering outlining the engineering of exosomes for surface display of proteins.
2/24/2021Life sciences companies across the globe are raking in investment dollars to advance drug programs.
Proceeds enable advancement of our exosome therapeutics into the clinic and expansion of our world-leading exosome platform
Evox Therapeutics Ltd, a leading exosome therapeutics company, announces that John McHutchison has joined its Board of Directors.
Grant protects a proprietary approach that enables luminal loading of soluble therapeutic proteins into exosomes
Collaboration with world-renowned research centre to accelerate development of exosome therapies for rare diseases
Further growth of leadership team with hire of highly experienced drug developer
Evox Therapeutics Expands Existing Exosome Patent Portfolio With Further Grant Covering Exosomes for RNA Therapeutics
Evox Therapeutics Ltd, a leading exosome therapeutics company, is pleased to announce that the Company has been granted a key patent by the United States Patent and Trademark Office.
Evox Therapeutics Announces a Multi-target RNAi and Antisense Research Collaboration and License Agreement With Lilly
Evox to use its proprietary exosome loading and CNS-targeting technologies to develop oligonucleotide drugs for the treatment of neurological disorders [09-June-2020] OXFORD, England , June 9, 2020 /PRNewswire/ -- Evox Therapeutics Ltd ('Evox' or the 'Company'), a leading exosome therapeutics company, is pleased to announce a research collaboration and license agreeme
5/29/2020Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Evox Therapeutics Ltd, a leading exosome therapeutics company, is pleased to announce the appointment of Martin Andrews as a Non-Executive Director.
Highly experienced physician with an excellent track record in clinical development at early stage biotech and big pharma
A seasoned executive with an extensive track record of global leadership in life sciences
CEVEC signs license agreement for the development and commercialization of exosomes for therapeutic use
CEVEC Pharmaceuticals GmbH announced the signing of a license agreement with Evox Therapeutics, Ltd. for the development and commercialization of therapeutic exosomes using CEVEC’s proprietary CAP® technology.
Collaboration focuses on developing novel protein replacement and mRNA therapies and explores the targeted delivery of these payloads using Evox's proprietary exosome technology Partnership encompasses up to five rare disease targets, including Evox's Niemann-Pick Type C programme, with Takeda assuming responsibility for its clinical development [26-March-2020]
The two companies plan to focus their efforts on targeting several rare diseases.
Evox Therapeutics Ltd, a leading exosome therapeutics company, is pleased to announce that the Company has been granted three key patents by the United States Patent and Trademark Office and the European Patent Office.
Evox Therapeutics Expands Leadership Team With the Appointment of Two Experienced Life Sciences Executives
Evox Therapeutics Ltd, a leading exosome therapeutics company, is pleased to announce the appointments of Bo Kara as VP Process Development and Simon Dew as VP of Business Development.
Proceeds will support advancement of an exosome therapy to treat a urea cycle disorder
Highly experienced life sciences executive with a track record of overseeing strong company growth and value creation